Ardsley Advisory Partners Boosts Holdings in Audentes Therapeutics, Inc. (NASDAQ:BOLD)

Ardsley Advisory Partners grew its stake in Audentes Therapeutics, Inc. (NASDAQ:BOLD) by 59.7% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,072 shares of the biotechnology company’s stock after acquiring an additional 7,500 shares during the quarter. Ardsley Advisory Partners owned about 0.07% of Audentes Therapeutics worth $384,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Wells Fargo & Company MN increased its position in shares of Audentes Therapeutics by 278.5% during the 1st quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 5,700 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Audentes Therapeutics by 36.2% during the 1st quarter. Bank of New York Mellon Corp now owns 18,843 shares of the biotechnology company’s stock worth $321,000 after purchasing an additional 5,009 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Audentes Therapeutics by 155.8% during the 1st quarter. Victory Capital Management Inc. now owns 73,914 shares of the biotechnology company’s stock worth $1,259,000 after purchasing an additional 45,024 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Audentes Therapeutics during the 1st quarter worth about $184,000. Finally, Bank of America Corp DE increased its position in shares of Audentes Therapeutics by 22.6% during the 1st quarter. Bank of America Corp DE now owns 23,399 shares of the biotechnology company’s stock worth $399,000 after purchasing an additional 4,310 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Ardsley Advisory Partners Boosts Holdings in Audentes Therapeutics, Inc. (NASDAQ:BOLD)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/27/ardsley-advisory-partners-boosts-position-in-audentes-therapeutics-inc-bold.html.

In other news, SVP Mary Newman sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $20.00, for a total value of $200,000.00. Following the transaction, the senior vice president now directly owns 10,000 shares of the company’s stock, valued at approximately $200,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Suyash Prasad sold 8,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $21.44, for a total value of $171,520.00. Following the completion of the transaction, the vice president now directly owns 8,000 shares in the company, valued at $171,520. The disclosure for this sale can be found here. Insiders sold a total of 766,500 shares of company stock worth $21,443,730 over the last three months. 47.30% of the stock is owned by company insiders.

Several equities analysts have weighed in on BOLD shares. Zacks Investment Research raised Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research report on Monday, July 17th. ValuEngine raised Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. Bank of America Corporation reiterated a “buy” rating and issued a $33.00 price objective (up previously from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. Raymond James Financial, Inc. initiated coverage on Audentes Therapeutics in a research note on Thursday, October 12th. They issued a “market perform” rating for the company. Finally, William Blair initiated coverage on Audentes Therapeutics in a research note on Tuesday, October 17th. They issued an “outperform” rating and a $35.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. Audentes Therapeutics currently has a consensus rating of “Buy” and an average price target of $25.71.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) traded up 0.12% during midday trading on Friday, reaching $25.42. The company had a trading volume of 37,305 shares. Audentes Therapeutics, Inc. has a 12 month low of $13.13 and a 12 month high of $33.43. The firm’s market capitalization is $706.27 million. The firm’s 50-day moving average price is $26.49 and its 200 day moving average price is $26.49.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.10). Equities analysts anticipate that Audentes Therapeutics, Inc. will post ($3.50) earnings per share for the current fiscal year.

Audentes Therapeutics Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply